180 related articles for article (PubMed ID: 34659553)
1. Synergistic killing effects of PD-L1-CAR T cells and colorectal cancer stem cell-dendritic cell vaccine-sensitized T cells in ALDH1-positive colorectal cancer stem cells.
Liu L; Liu Y; Xia Y; Wang G; Zhang X; Zhang H; Xu Y; Yuan Y; Liu S; Wang Y
J Cancer; 2021; 12(22):6629-6639. PubMed ID: 34659553
[TBL] [Abstract][Full Text] [Related]
2. Colorectal cancer stem cell vaccine with high expression of MUC1 serves as a novel prophylactic vaccine for colorectal cancer.
Guo M; Luo B; Pan M; Li M; Xu H; Zhao F; Dou J
Int Immunopharmacol; 2020 Nov; 88():106850. PubMed ID: 32777675
[TBL] [Abstract][Full Text] [Related]
3. MUC1 plays an essential role in tumor immunity of colorectal cancer stem cell vaccine.
Guo M; Luo B; Pan M; Li M; Zhao F; Dou J
Int Immunopharmacol; 2020 Aug; 85():106631. PubMed ID: 32470879
[TBL] [Abstract][Full Text] [Related]
4. The surface dominant antigen MUC1 is required for colorectal cancer stem cell vaccine to exert anti-tumor efficacy.
Guo M; You C; Dong W; Luo B; Wu Y; Chen Y; Li J; Pan M; Li M; Zhao F; Dou J
Biomed Pharmacother; 2020 Dec; 132():110804. PubMed ID: 33017767
[TBL] [Abstract][Full Text] [Related]
5. Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model.
Zheng F; Dang J; Zhang H; Xu F; Ba D; Zhang B; Cheng F; Chang AE; Wicha MS; Li Q
J Immunother; 2018 Oct; 41(8):361-368. PubMed ID: 30063587
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of an ALDH peptide-based dendritic cell vaccine targeting cancer stem cells.
Liao F; Zhang J; Hu Y; Najafabadi AH; Moon JJ; Wicha MS; Kaspo B; Whitfield J; Chang AE; Li Q
Cancer Immunol Immunother; 2022 Aug; 71(8):1959-1973. PubMed ID: 35098344
[TBL] [Abstract][Full Text] [Related]
7. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
Zhang A; Sun Y; Wang S; Du J; Gao X; Yuan Y; Zhao L; Yang Y; Xu L; Lei Y; Duan L; Xu C; Ma L; Wang J; Hu G; Chen H; Wang Q; Hu L; Zhang B
Cytotherapy; 2020 Dec; 22(12):734-743. PubMed ID: 32684339
[TBL] [Abstract][Full Text] [Related]
8. A novel PD-L1-targeted shark V
Li D; English H; Hong J; Liang T; Merlino G; Day CP; Ho M
Mol Ther Oncolytics; 2022 Mar; 24():849-863. PubMed ID: 35317524
[TBL] [Abstract][Full Text] [Related]
9. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo.
Liao Q; Mao Y; He H; Ding X; Zhang X; Xu J
Biomark Res; 2020 Nov; 8(1):57. PubMed ID: 33292688
[TBL] [Abstract][Full Text] [Related]
11. Improving immunotherapy for colorectal cancer using dendritic cells combined with anti-programmed death-ligand
Hu Z; Ma Y; Shang Z; Hu S; Liang K; Liang W; Xing X; Wang Y; Du X
Oncol Lett; 2018 Apr; 15(4):5345-5351. PubMed ID: 29552177
[TBL] [Abstract][Full Text] [Related]
12. Lentivirus-mediated RNA interference targeting programmed death receptor ligand 1 increases the immunologic anti-tumor effect of dendritic cell vaccination against pancreatic cancer in SCID-hu mice.
Wang J; Sun M; Zhu X; Zhao H; Mao D; Zhang Z; Zhao X
Oncol Lett; 2019 Aug; 18(2):1539-1547. PubMed ID: 31423221
[TBL] [Abstract][Full Text] [Related]
13. PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine.
Shi X; Zhang X; Li J; Mo L; Zhao H; Zhu Y; Hu Z; Gao J; Tan W
Int J Cancer; 2018 May; 142(10):2106-2117. PubMed ID: 29243219
[TBL] [Abstract][Full Text] [Related]
14. Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer.
Yang CY; Fan MH; Miao CH; Liao YJ; Yuan RH; Liu CL
Mol Ther Oncolytics; 2020 Jun; 17():571-585. PubMed ID: 32637575
[TBL] [Abstract][Full Text] [Related]
15. Programmed death-ligand 1 expression on CD22-specific chimeric antigen receptor-modified T cells weakens antitumor potential.
Liu J; Zhang F; Yu J; Zhao Q
MedComm (2020); 2022 Jun; 3(2):e140. PubMed ID: 35665369
[TBL] [Abstract][Full Text] [Related]
16. Targeting stemness of cancer stem cells to fight colorectal cancers.
Du L; Cheng Q; Zheng H; Liu J; Liu L; Chen Q
Semin Cancer Biol; 2022 Jul; 82():150-161. PubMed ID: 33631296
[TBL] [Abstract][Full Text] [Related]
17. Central memory phenotype drives success of checkpoint inhibition in combination with CAR T cells.
Toews K; Grunewald L; Schwiebert S; Klaus A; Winkler A; Ali S; Zirngibl F; Astrahantseff K; Wagner DL; Henssen AG; Deubzer HE; Schulte JH; Ochsenreither S; Eggert A; Künkele A
Mol Carcinog; 2020 Jul; 59(7):724-735. PubMed ID: 32333465
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
19. GTP binding protein 2 maintains the quiescence, self-renewal, and chemoresistance of mouse colorectal cancer stem cells via promoting Wnt signaling activation.
Ke C; Zhou H; Xia T; Xie X; Jiang B
Heliyon; 2024 Mar; 10(5):e27159. PubMed ID: 38468952
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cells loaded with CD44
Fu C; Zhou N; Zhao Y; Duan J; Xu H; Wang Y
Oncol Lett; 2019 Dec; 18(6):5897-5904. PubMed ID: 31788063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
